People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Veralox Therapeutics Inc. | — | Biotechnology | Series B | $39.9M | $272.8M | 2023 |
Megan Krench at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Megan Krench on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Mow | 1 | 3 |
| Katie Ellias | 1 | 3 |
| Benjamin Scruggs | 1 | 3 |
| Alex Martin | 1 | 2 |
| Jamie Stiff | 1 | 1 |
| Benjamin W. Scruggs | 1 | 1 |
| Jeffrey W. Strovel | 1 | 1 |
| Jamie W. Stiff | 1 | 1 |
| Katie W. Ellias | 1 | 1 |
| Christopher W. Gagliardi | 1 | 1 |
| Alex W. Martin | 1 | 1 |
| David W. Maloney | 1 | 1 |
| Jonathan W. Behr | 1 | 1 |
| Matthew W. Boxer | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.